Avenue Therapeutics

ATXI · OTC

$0.4042−$0.0258 (−6.00%)TodayMarket closed · Oct 20, 2:05 PM ET

No price history for this range.

About ATXI

Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. The company is headquartered in Bay Harbor Islands, Florida and currently employs 1 full-time employees. The company went IPO on 2017-06-27. The firm is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patient’s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.

Employees: 1
Headquarters: Bay Harbor Islands, Florida
Listed: Jun 27, 2017
Sector: Health Care
Industry: Pharmaceuticals
Website: avenuetx.com

Leadership

Avenue Therapeutics executives
Name	Title	Since	Age
Jay Kranzler	—	—	67
Alexandra Maclean	—	2022	58
David Jin	—	—	35
Lindsay Rosenwald	—	2015	69
Faith Charles	—	—	63
Neil Herskowitz	—	—	68
Curtis Oltmans	—	—	61
Jaclyn Jaffe	—	2022	—

Similar companies

Companies in the same industry as Avenue Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.